Extension of NetraMark’s NetraPharma Collaboration with Juvenescence
December 10, 2019
NetraMark Corp., a next generation AI + health data technology company and Juvenescence Limited, a life sciences company utilizing expert drug developers and artificial intelligence experts to create therapeutics and technologies to treat diseases of aging and to increase human longevity, are pleased to announce the extension of their collaboration agreement to include drug repurposing and drug discovery.
Dr. Joseph Geraci, CEO of NetraMark, said: “After years of development and validation by the NetraMark tech team, the NetraAI machine learning suite is providing us with valuable insights into aging. The result is a very exciting collaboration with Juvenescence, one of the premier biotech companies focusing on modifying aging. Their efforts provide a perfect application of our solution which allows us, unlike other AI companies, to extract valuable and clear insights from limited data sets, to provide novel therapeutics for complex disorders like aging.”
NetraMark is a Toronto-based tech venture with dedicated solutions for pharmaceutical and biotech companies. NetraMark’s AI platform was designed to extract insights from complex patient populations for patient stratification, placebo response prediction, drug repurposing, and precision multi-target identification. The AI paradigm was discovered by CEO Dr. Joseph Geraci, a mathematician, medical scientist, and quantum machine learning specialist who began commercializing the idea in 2017 with the help of COO Richard Brooks, a business lawyer and serial entrepreneur who has supported Canadian start-ups for more than 20 years. For more information, please visit netramark.com
ABOUT JUVENESCENCE LTD.
Juvenescence Limited is a life sciences company developing therapies to modify aging and increase healthy human longevity. It was founded by
Link to the Press Release found here.